Exicure received a Nasdaq extension through December 2, 2026, to regain compliance with the minimum $2.5 million stockholders' equity requirement after failing initial listing standards in June 2026. The company must demonstrate compliance by this deadline or face potential delisting proceedings. Exicure is a biotechnology company.

Exicure, Inc. expanded its Board of Directors from five to six members effective June 30, 2026, and formed a new Compensation Committee. Ham Jung Kyu resigned from the Board on June 24, 2026, and was replaced by Go Jin Young, while Han Eui Seok was appointed to the newly created Class III director seat. Exicure, Inc. operates in the technology sector, providing security and identity management solutions.